drugset / Trial / NCT00985777
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
Phase 1
Completed
26 enrolled
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safest dose of the study drug Vitamin E Delta-tocotrienol, how often it should be taken, and how well people with pancreatic tumors tolerate Vitamin E Delta-tocotrienol.
Timeline
- Start
- 2009-09
- Primary completion
- 2015-06
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin E δ-Tocotrienol | Unknown | 200 mg | Oral |
| Subject | Vitamin E δ-Tocotrienol | Unknown | 3200 mg | Oral |